Granite Point Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Granite Point Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,500	Closed	-$551K	–	101
2016 Q3	$551K	Sell	4,500 -5,500	-55%	-$708K	0.22%	66
2016 Q2	$1.17M	Buy	+10,000	New	+$1.42M	0.5%	34
2015 Q3	–	Sell	-1,555	Closed	-$281K	–	107
2015 Q2	$281K	Sell	1,555 -845	-35%	-$146K	0.08%	89
2015 Q1	$416K	Hold	2,400	–	–	0.15%	80
2014 Q4	$444K	Sell	2,400 -300	-11%	-$55.6K	0.21%	65
2014 Q3	$448K	Hold	2,700	–	–	0.22%	70
2014 Q2	$422K	Sell	2,700 -1,000	-27%	-$158K	0.29%	67
2014 Q1	$563K	Sell	3,700 -6,300	-63%	-$1M	0.4%	78
2013 Q4	$1.33M	Buy	+10,000	New	+$1.2M	0.22%	48

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Granite Point Capital Management's ALXN Position: Q4 2016 in Review

Granite Point Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 4,500 shares — an estimated $551K sold.

Granite Point Capital Management first reported a position in ALXN in Q4 2013 and held it in 9 quarters. The position peaked at $1.33M in Q4 2013. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Granite Point Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Granite Point Capital Management sold 4,500 Alexion Pharmaceuticals shares in Q4 2016, an estimated $551K.
Granite Point Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 9 quarters.
Granite Point Capital Management's Alexion Pharmaceuticals position peaked at $1.33M in Q4 2013.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Granite Point Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.